Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pro-glucagon (Homo sapiens (Human)) | BDBM2437 (US8507533, 157) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 5.55 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100827 (US8507533, 138 | US8507533, 151 | US8507533, 374) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 5.75 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100806 (US8507533, 114 | US8507533, 115 | US8507533, 330) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 7.60 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2390 (US8507533, 146) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 9.05 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM142039 (US8927577, 118 | US8927577, 20 | US8927577, 35) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 14 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun... | US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100806 (US8507533, 114 | US8507533, 115 | US8507533, 330) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 15.8 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100796 (US8507533, 101) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 17 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100827 (US8507533, 138 | US8507533, 151 | US8507533, 374) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 20.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2376 (US8507533, 137) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 20.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM142041 (US8927577, 22) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 25 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun... | US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100844 (US8507533, 160 | US8507533, 398) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 25.7 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2391 (US8507533, 147) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 26.7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100850 (US8507533, 168) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 27.4 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100852 (US8507533, 170 | US8507533, 419) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 28 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100844 (US8507533, 160 | US8507533, 398) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 29 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100822 (US8507533, 129 | US8507533, 162 | US8507533, 399) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 29.3 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2241 (US8507533, 136) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 30.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100838 (US8507533, 153) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 32.3 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM160576 (US9045389, 8) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 33 | -9.48 | n/a | n/a | n/a | n/a | n/a | 7.4 | 4 |
Janssen Pharmaceutica NV US Patent | Assay Description Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und... | US Patent US9045389 (2015) BindingDB Entry DOI: 10.7270/Q2D21WC3 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2240 (US8507533, 135) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 35 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100837 (US8507533, 152) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 35.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM160577 (US9045389, 9) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 38 | -9.40 | n/a | n/a | n/a | n/a | n/a | 7.4 | 4 |
Janssen Pharmaceutica NV US Patent | Assay Description Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und... | US Patent US9045389 (2015) BindingDB Entry DOI: 10.7270/Q2D21WC3 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100805 (US8507533, 113) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 38.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM142039 (US8927577, 118 | US8927577, 20 | US8927577, 35) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 39 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun... | US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2438 (US8507533, 158) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 41 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100861 (US8507533, 188) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | Purchase PC cid PC sid PDB UniChem Similars | US Patent | 42.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100864 (US8507533, 193) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 44.7 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM160575 (US9045389, 7) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 45 | -9.31 | n/a | n/a | n/a | n/a | n/a | 7.4 | 4 |
Janssen Pharmaceutica NV US Patent | Assay Description Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und... | US Patent US9045389 (2015) BindingDB Entry DOI: 10.7270/Q2D21WC3 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100815 (US8507533, 122) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 45.7 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100822 (US8507533, 129 | US8507533, 162 | US8507533, 399) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 47.3 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2229 (US8507533, 187 | US8507533, 448) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 47.8 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM142042 (US8927577, 23) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 50 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun... | US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100824 (US8507533, 131) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 51 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM142038 (US8927577, 117 | US8927577, 19 | US8927577, 32) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 53 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun... | US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100801 (US8507533, 109 | US8507533, 322) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 57.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM2387 (US8507533, 143) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 57.4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100826 (US8507533, 133) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 58 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM160583 (US9045389, 18) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 60 | -9.15 | n/a | n/a | n/a | n/a | n/a | 7.4 | 4 |
Janssen Pharmaceutica NV US Patent | Assay Description Full-length human GCGR (Accession Number: NM000160) subcloned into pcDNA3.1 was stably transfected into HEK293 cells (hGluc-1 HEK) and maintained und... | US Patent US9045389 (2015) BindingDB Entry DOI: 10.7270/Q2D21WC3 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100831 (US8507533, 144) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 62.6 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100829 (US8507533, 140) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 62.8 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100847 (US8507533, 163) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 65.9 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100797 (US8507533, 105) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 69.8 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100799 (US8507533, 107) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 71.6 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM142038 (US8927577, 117 | US8927577, 19 | US8927577, 32) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 74 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun... | US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM142030 (US8927577, 11 | US8927577, 30 | US8927577, 31) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 76 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun... | US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100856 (US8507533, 181) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 87.2 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100816 (US8507533, 123) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 88.4 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100830 (US8507533, 141) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 89.5 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM142035 (US8927577, 16) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 91 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun... | US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Pro-glucagon (Homo sapiens (Human)) | BDBM100798 (US8507533, 106) | PDB Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 91.9 | n/a | n/a | n/a | n/a | n/a | n/a | 7.4 | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 122 total ) | Next | Last >> |